MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Zafgen Company Profile (NASDAQ:ZFGN)

Consensus Ratings for Zafgen (NASDAQ:ZFGN) (?)
Ratings Breakdown: 4 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $13.17 (125.07% upside)

Analysts' Ratings History for Zafgen (NASDAQ:ZFGN)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016Leerink SwannReiterated RatingHold$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016RBC CapitalReiterated RatingOutperform$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2016Canaccord GenuityDowngradeBuy -> Hold$30.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/20/2016SunTrustReiterated RatingHold$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2015Cowen and CompanyReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/16/2015JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Zafgen (NASDAQ:ZFGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/10/2016Q116($0.74)($0.65)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.80)($0.85)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q3($0.79)($0.73)$80.60 million$78.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.71)($0.66)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.52)($0.53)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2015Q414($0.84)($0.48)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314($0.87)($0.65)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014Q214($0.28)($2.96)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Zafgen (NASDAQ:ZFGN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.75)($0.75)($0.75)
Q2 20162($0.66)($0.62)($0.64)
Q3 20162($0.76)($0.68)($0.72)
Q4 20162($0.89)($0.69)($0.79)
(Data provided by Zacks Investment Research)
Dividend History for Zafgen (NASDAQ:ZFGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Zafgen (NASDAQ:ZFGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/12/2016James E FlynnInsiderBuy64,545$6.25$403,406.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2016James E FlynnInsiderBuy267,493$6.02$1,610,307.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2015Kevin P StarrDirectorSell136,579$43.90$5,995,818.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Avi Y GoldbergDirectorSell5,000$45.00$225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Thomas E. HughesCEOSell45,626$42.53$1,940,473.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2015Dennis D. KiminsiderSell39,407$40.00$1,576,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Avi Y GoldbergDirectorSell3,000$35.00$105,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Avi Y GoldbergDirectorSell2,000$32.23$64,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2014Alicia SecorInsiderBuy4,000$20.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Zafgen (NASDAQ:ZFGN)
DateHeadline
06/24/16 07:24 PMImpact Score Outlook on:Zafgen, Inc. (NASDAQ:ZFGN) - Press Telegraph
06/24/16 07:24 PMTracking Share Activity for: Zafgen, Inc. (NASDAQ:ZFGN) - Press Telegraph
06/24/16 07:24 PMConsensus View on Zafgen, Inc. (NASDAQ:ZFGN) Stock and Check on Movement - Press Telegraph
06/23/16 08:15 PMZafgen, Inc. (NASDAQ:ZFGN): Share Update and Performance Review - Press Telegraph
06/23/16 08:15 PMChecking in on Consensus Views for Zafgen, Inc. (NASDAQ:ZFGN) - Press Telegraph
06/23/16 08:15 PMStock Watch for: Zafgen, Inc. (NASDAQ:ZFGN) - Press Telegraph
06/23/16 09:56 AMZafgen, Inc. (NASDAQ:ZFGN) Stock Momentum Hits Weakness - CML News
06/20/16 08:44 AMThis Weeks Broker Views For Zafgen, Inc. (NASDAQ:ZFGN) - Fiscal Standard
06/18/16 04:31 AMRecently Issued Stock Ratings For Zafgen, Inc. (NASDAQ:ZFGN) - Fiscal Standard
06/14/16 07:00 PMZafgen''s Beloranib Trial Shows Significant Improvements In Weight Loss
06/13/16 06:49 PMZafgen (ZFGN) Presents Favorable New Data on Beloranib - Nasdaq
06/13/16 08:36 AMZafgen up 6% after weight loss drug has positive late-stage trial results -
06/12/16 11:39 PM12:39 am Zafgen reports Phase 2b data for Beloranib demonstrating statistically and clinically significant improvements in body weight, body composition, and glycemic control -
06/11/16 10:09 AMZafgen Presents New Data from the Phase 2b Clinical Trial Evaluating Beloranib in Severe Obesity Complicated by Type 2 Diabetes at the American Diabetes Association's 76th Scientific Sessions - [at noodls] - NEW ORLEANS, June 11, 2016 (GLOBE NEWSWIRE) -- Zafgen Inc. (NASDAQ:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and ...
06/10/16 07:53 PMTrend Of Rating Given To Zafgen, Inc. (NASDAQ:ZFGN) - Investor Newswire
06/08/16 10:37 AMZAFGEN INC. (NASDAQ:ZFGN) Financial Condition Compared to S&P 500 - CML News
06/06/16 01:28 PMZafgen, Inc. :ZFGN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/05/16 07:29 PMNext Weeks Broker Price Targets For Zafgen, Inc. (NASDAQ:ZFGN) - Share Trading News
06/03/16 08:12 PMZafgen Inc. (ZFGN) is Trading Higher on Unusual Volume for June 02 - Equities.com
06/02/16 08:01 PMZafgen, Inc. (NASDAQ:ZFGN) Near Term Target Update - Stock Tick Tock - Zafgen, Inc. (NASDAQ:ZFGN) Near Term Target UpdateStock Tick TockSell-siders covering shares of Zafgen, Inc. (NASDAQ:ZFGN) have a consensus price target of $17 for the next 12-18 months. Analysts study the companies they cover in order to present the sell-side institutions with the information needed to make ...and more »
06/02/16 08:01 PMZafgen, Inc. (NASDAQ:ZFGN): Rundown on Share Performance - HNN - Zafgen, Inc. (NASDAQ:ZFGN): Rundown on Share PerformanceHNNIn the latest trading period, Zafgen, Inc. (NASDAQ:ZFGN) shares have seen a change of +4.79%. During the period, the stock has moved up to a high of $7.73 and dipped to a low of $7.00. Looking at a broader view of stock performance, shares have range ...and more »
06/02/16 08:01 PMTarget Price Outlook on Zafgen, Inc. (NASDAQ:ZFGN) - HNN - Target Price Outlook on Zafgen, Inc. (NASDAQ:ZFGN)HNNEquity analysts that track Zafgen, Inc. (NASDAQ:ZFGN) shares have provided targets on where they believe the stock will move in the future. The present consensus target price compiled using analysts polled by Zacks Research sits at $17. There are 6 ...and more »
06/01/16 10:31 AMStock Review and Earnings Check on Zafgen, Inc. (NASDAQ:ZFGN) - HNN - Stock Review and Earnings Check on Zafgen, Inc. (NASDAQ:ZFGN)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Zafgen, Inc. (NASDAQ:ZFGN) to ...and more »
05/31/16 07:53 PMStock Performance Check on : Zafgen, Inc. (NASDAQ:ZFGN) - HNN - Stock Performance Check on : Zafgen, Inc. (NASDAQ:ZFGN)HNNTracking share activity in recent trading action, shares of Zafgen, Inc. have been recorded 33.52% away from the 52 week low. Company shares have been recently seen -85.14% off of the 52 week high. The stock has been trading at 27.32% separated from ...and more »
05/28/16 10:41 AMView on Earnings Zafgen, Inc. (NASDAQ:ZFGN) - HNN - View on Earnings Zafgen, Inc. (NASDAQ:ZFGN)HNNSell-side analysts that cover Zafgen, Inc. (NASDAQ:ZFGN) are expecting the company to report earnings for the quarter of $-0.67. The consensus estimate uses covering analysts polled by Zacks Research. The estimate may vary from what other data ...
05/27/16 11:46 AMTarget Price Review Zafgen, Inc. (NASDAQ:ZFGN) - Wall Street Hints and News - Target Price Review Zafgen, Inc. (NASDAQ:ZFGN)Wall Street Hints and NewsShares of Zafgen, Inc. (NASDAQ:ZFGN) currently have a consensus target price of $17. The analyst with the most aggressive target price according data provided by Zacks Research, is presently $30. The analyst with the bottom target estimate on shares ...and more »
05/27/16 11:46 AMZafgen, Inc. (NASDAQ:ZFGN) Impact Score At 0 - RealistInvestor.com - Zafgen, Inc. (NASDAQ:ZFGN) Impact Score At 0RealistInvestor.comAlpha One explored various online articles released on Zafgen, Inc. (NASDAQ:ZFGN), and it set a daily sentiment score of 0 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content issued on ...and more »
05/27/16 11:46 AMZafgen, Inc. (NASDAQ:ZFGN) News Sentiment Review - Wall Street Hints and News - Zafgen, Inc. (NASDAQ:ZFGN) News Sentiment ReviewWall Street Hints and NewsZafgen, Inc. (NASDAQ:ZFGN) has a present news sentiment score of 0. This score is given by Beta Research using a scale from 1 to -1. A 1 score may indicate positive news sentiment while a score of -1 may indicate the opposite. Zafgen, Inc.
05/26/16 10:51 AMEarnings Review and Stock Rundown for Zafgen, Inc. (NASDAQ:ZFGN) - Wall Street Hints and News - Earnings Review and Stock Rundown for Zafgen, Inc. (NASDAQ:ZFGN)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Zafgen, Inc. (NASDAQ:ZFGN) to post ...and more »
05/26/16 10:51 AMZafgen, Inc. (NASDAQ:ZFGN) Updated Broker Price Targets - Share Trading News - Zafgen, Inc. (NASDAQ:ZFGN) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Zafgen, Inc. (NASDAQ:ZFGN). The latest reports which are currently in issue on Thursday 26th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...
05/19/16 12:04 PMZAFGEN, INC. Financials -
05/11/16 10:20 AM​Hopes rise for FDA approval of Zafgen’s fat-busting drug among analysts, investors -
05/10/16 05:14 PMZafgen reports 1Q loss -
05/10/16 03:28 PMZafgen Reports First Quarter 2016 Financial Results - [at noodls] - BOSTON, May 10, 2016 (GLOBE NEWSWIRE) -- Zafgen (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic ...
05/03/16 03:20 PMZafgen to Host Conference Call to Discuss First Quarter 2016 Financial Results - [at noodls] - BOSTON, May 03, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex ...
04/11/16 02:03 PMZafgen Management Really Believes It Will Have Clinical Hold Removed; Decision Could Come In 4-6 Months, Analyst Says - Leerink said Zafgen Inc (NASDAQ: ZFGN) management believes it will have clinical hold removed on beloranib and the brokerage expects a FDA decision in the next 4-6 months. In December 2015, the FDA placed a clinical hold on beloranib investigational new drug (IND) application to treat Prader-Willi syndrome (PWS), a genetic disorder that causes learning difficulties, growth abnormalities, and obsessive eating. "We expect the beloranib (Prader-Willi Syndrome [PWS]) risk mitigation proposal submitted by ZFGN to the FDA to present strong reasoning for removal of the full clinical hold; however, we continue to believe the threshold for establishing a positive risk/ benefit argument remains high, a decision is likely several months away, and it is difficult to handicap the FDA's response," analysts including Joseph Schwartz wrote in a note to clients. "Although the timing of ZFGN's complete response submission remains vague, we estimate that an FDA decision on removing or maintaining the clinical hold could be reached in 4-6 months," the analyst continued. Schwartz noted that the next milestone is a Type A meeting ...Full story available on Benzinga.com
04/06/16 12:53 PMEdited Transcript of ZFGN earnings conference call or presentation 9-Mar-16 9:30pm GMT -
04/04/16 10:42 AMPenny Stocks To Buy: Traders Are Considering Stocks On This List, Monday 4/4/2016 - [Accesswire] - MIAMI, FL / ACCESSWIRE / April 4, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. ZFGN, CNAT, CRC, and TRTC have been added to our watch list today. Continue reading to find out ...
04/04/16 09:21 AMZafgen (ZFGN) Stock Surges on Positive Obesity Drug Trial -
04/04/16 08:32 AMZafgen Shares Surge On Positive Phase 3 Trial - Shares of Zafgen Inc (NASDAQ: ZFGN) gained more than 14 percent early Monday morning after the company announced positive data from a Phase 3 trial evaluating the safety and efficacy of beloranib. The study evaluated the safety and efficacy of beloranib, a MetAP2 inhibitor, in patients with Prader-Wili syndrome (PWS) over six months. The data showed beloranib was associated with improvement in total cholesterol, LDL cholesterol and other cardio-metabolic risk factors, and a reduction of fat mass when compared to a ...Full story available on Benzinga.com
04/03/16 12:35 PMZafgen Presents New Data from the Phase 3 bestPWS Study Evaluating Beloranib in Prader-Willi Syndrome at ENDO 2016 - [at noodls] - --bestPWS Study is the first Phase 3 pivotal trial to show significant weight-loss and improvement in hyperphagia-related behaviors in PWS patients-- --Beloranib was associated with improvement in total ...
03/14/16 11:01 AMStock News Impact Score: Zafgen, Inc. (NASDAQ:ZFGN) - Business Standard Tribune - Stock News Impact Score: Zafgen, Inc. (NASDAQ:ZFGN)Business Standard TribuneShares of Zafgen, Inc. (NASDAQ:ZFGN) have grabbed recent news attention. According to Beta Research, Zafgen, Inc. has been given an impact score of 50. The impact score represents an average projection of how reported news in the previous day may ...and more »
03/10/16 02:16 PMZafgen (ZFGN) Stock Sinks on Q4 Loss -
03/09/16 03:55 PMZafgen reports 4Q loss -
03/09/16 03:20 PMZAFGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/09/16 03:05 PMZafgen Reports Fourth Quarter and Full Year 2015 Financial Results - [GlobeNewswire] - BOSTON, March 09, 2016-- Zafgen, a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced ...
03/08/16 04:02 PMZAFGEN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial State -
03/02/16 03:00 PMZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results - [GlobeNewswire] - BOSTON, March 02, 2016-- Zafgen, Inc., a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced ...
03/01/16 06:00 AMZafgen to Present at the Cowen & Company 36th Annual Health Care Conference - [GlobeNewswire] - BOSTON, March 01, 2016-- Zafgen, Inc., a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced ...
02/29/16 06:00 AMZafgen Joins NORD in Raising Awareness of Rare Disease Day - [GlobeNewswire] - BOSTON, Feb. 29, 2016-- Zafgen Inc., a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced ...
About Zafgen

Zafgen logoZafgen, Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity. Beloranib is in Phase III stage of development for obesity and hyperphagia in patients with PWS; completed Phase II clinical trial for HIAO, and is in Phase IIb stage of development for severe obesity in the general population. The Company's other product candidate, ZGN-839, is in pre-clinical development stage. The Company is also evaluating the additional MetAP2 inhibitors beyond Beloranib as potential development candidates for the treatment of severe obesity.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ZFGN
  • CUSIP:
Key Metrics:
  • Previous Close: $6.28
  • 50 Day Moving Average: $6.54
  • 200 Day Moving Average: $6.60
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $159.54M
  • Current Quarter EPS Consensus Estimate: $-2.81 EPS
Additional Links:
Zafgen (NASDAQ:ZFGN) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha